Heron Therapeutics Inc (HRTX) FinancialsHRTXFinancialHeron Therapeutics Inc

Heron Therapeutics Inc (HRTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is CINVANTI, accounting for 57.9% of total sales, equivalent to $21.79M. Other significant revenue streams include ZYNRELEF and APONVIE. Understanding this composition is critical for investors evaluating how HRTX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Heron Therapeutics Inc maintains a gross margin of 69.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.43%, while the net margin is -14.57%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HRTX converts its operational activities into shareholder value.

In the context of the broader market, HRTX competes directly with industry leaders such as BSEM and ELOX. With a market capitalization of $62.01M, it holds a significant position in the sector. When comparing efficiency, HRTX's gross margin of 69.28% stands against BSEM's 52.55% and ELOX's N/A. Such benchmarking helps identify whether Heron Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Heron Therapeutics has shown fluctuating revenue with a slight increase in Q2 2026 to $37.67 million, but this is overshadowed by rising losses and a withdrawal of financial guidance for 2026. The gross margin has decreased to 69% from previous highs, reflecting pressure on profitability.